ORIC PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense
ORIC PHARMACEUTICALS, INC. (ORIC) reported Share-based Payment Arrangement, Expense of $7.09 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-03
- ORIC PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $7.09M, a 7.86% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $6.90M, a 5.25% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $6.28M, a 20.66% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $5.63M, a 11.37% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2025 was $25.04M, a 23.87% increase from fiscal 2024.
- ORIC PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2024 was $20.21M, a 32.75% increase from fiscal 2023.
- ORIC PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2023 was $15.23M, a 5.30% increase from fiscal 2022.
- ORIC PHARMACEUTICALS, INC. share-based payment arrangement, expense for fiscal 2022 was $14.46M, a 12.50% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $7.09M 10-Q · filed 2026-08-03 | $13.99M 10-Q · filed 2026-08-03 | $20.27M derived: sum of 3 quarters · filed 2026-08-03 | $25.90M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2026-03-31 | $6.90M 10-Q · filed 2026-05-04 | $13.18M derived: sum of 2 quarters · filed 2026-05-04 | $18.81M derived: sum of 3 quarters · filed 2026-05-04 | $25.38M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-12-31 | $6.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $11.91M derived: sum of 2 quarters · filed 2026-02-23 | $18.48M derived: sum of 3 quarters · filed 2026-08-03 | $25.04M 10-K · filed 2026-02-23 | |
| 2025-09-30 | $5.63M 10-Q · filed 2025-11-13 | $12.21M derived: sum of 2 quarters · filed 2026-08-03 | $18.76M 10-Q · filed 2025-11-13 | $23.96M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-06-30 | $6.57M 10-Q · filed 2026-08-03 | $13.13M 10-Q · filed 2026-08-03 | $18.33M derived: sum of 3 quarters · filed 2026-08-03 | $23.39M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-03-31 | $6.55M 10-Q · filed 2026-05-04 | $11.76M derived: sum of 2 quarters · filed 2026-05-04 | $16.81M derived: sum of 3 quarters · filed 2026-05-04 | $21.81M derived: sum of 4 quarters · filed 2026-05-04 | |
| 2024-12-31 | $5.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $10.26M derived: sum of 2 quarters · filed 2026-02-23 | $15.26M derived: sum of 3 quarters · filed 2026-02-23 | $20.21M 10-K · filed 2026-02-23 | |
| 2024-09-30 | $5.06M 10-Q · filed 2025-11-13 | $10.05M derived: sum of 2 quarters · filed 2025-11-13 | $15.01M 10-Q · filed 2025-11-13 | $18.93M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $5.00M 10-Q · filed 2025-08-12 | $9.95M 10-Q · filed 2025-08-12 | $13.88M derived: sum of 3 quarters · filed 2025-08-12 | $17.74M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $4.96M 10-Q · filed 2025-05-05 | $8.88M derived: sum of 2 quarters · filed 2025-05-05 | $12.74M derived: sum of 3 quarters · filed 2025-05-05 | $16.57M derived: sum of 4 quarters · filed 2025-05-05 | |
| 2023-12-31 | $3.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $7.79M derived: sum of 2 quarters · filed 2025-02-18 | $11.61M derived: sum of 3 quarters · filed 2025-02-18 | $15.23M 10-K · filed 2025-02-18 | |
| 2023-09-30 | $3.86M 10-Q · filed 2024-11-12 | $7.69M derived: sum of 2 quarters · filed 2024-11-12 | $11.30M 10-Q · filed 2024-11-12 | $14.43M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $3.83M 10-Q · filed 2024-08-12 | $7.44M 10-Q · filed 2024-08-12 | $10.57M derived: sum of 3 quarters · filed 2024-08-12 | $13.86M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | $3.61M 10-Q · filed 2024-05-06 | $6.74M derived: sum of 2 quarters · filed 2024-05-06 | $10.04M derived: sum of 3 quarters · filed 2024-05-06 | $14.13M derived: sum of 4 quarters · filed 2024-05-06 | |
| 2022-12-31 | $3.13M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $6.42M derived: sum of 2 quarters · filed 2024-03-11 | $10.52M derived: sum of 3 quarters · filed 2024-03-11 | $14.46M 10-K · filed 2024-03-11 | |
| 2022-09-30 | $3.29M 10-Q · filed 2023-11-06 | $7.38M derived: sum of 2 quarters · filed 2023-11-06 | $11.33M 10-Q · filed 2023-11-06 | $14.83M derived: sum of 4 quarters · filed 2023-11-06 | |
| 2022-06-30 | $4.09M 10-Q · filed 2023-08-10 | $8.04M 10-Q · filed 2023-08-10 | $11.54M derived: sum of 3 quarters · filed 2023-08-10 | $14.93M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $3.94M 10-Q · filed 2023-05-08 | $7.44M derived: sum of 2 quarters · filed 2023-05-08 | $10.84M derived: sum of 3 quarters · filed 2023-05-08 | $14.05M derived: sum of 4 quarters · filed 2023-05-08 | |
| 2021-12-31 | $3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $6.90M derived: sum of 2 quarters · filed 2023-03-16 | $10.11M derived: sum of 3 quarters · filed 2023-03-16 | $12.85M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $3.40M 10-Q · filed 2022-11-07 | $6.61M derived: sum of 2 quarters · filed 2022-11-07 | $9.35M 10-Q · filed 2022-11-07 | $11.04M derived: sum of 4 quarters · filed 2022-11-07 | |
| 2021-06-30 | $3.21M 10-Q · filed 2022-08-11 | $5.96M 10-Q · filed 2022-08-11 | $7.65M derived: sum of 3 quarters · filed 2022-08-11 | $9.33M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $2.74M 10-Q · filed 2022-05-09 | $4.43M derived: sum of 2 quarters · filed 2022-05-09 | $6.11M derived: sum of 3 quarters · filed 2022-05-09 | $7.50M derived: sum of 4 quarters · filed 2022-05-09 | |
| 2020-12-31 | $1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $3.37M derived: sum of 2 quarters · filed 2022-03-21 | $4.75M derived: sum of 3 quarters · filed 2022-03-21 | $5.28M 10-K · filed 2022-03-21 | |
| 2020-09-30 | $1.68M 10-Q · filed 2021-11-08 | $3.06M derived: sum of 2 quarters · filed 2021-11-08 | $3.59M 10-Q · filed 2021-11-08 | $4.03M derived: sum of 4 quarters · filed 2022-03-21 | |
| 2020-06-30 | $1.38M 10-Q · filed 2021-08-10 | $1.91M 10-Q · filed 2021-08-10 | $2.35M derived: sum of 3 quarters · filed 2022-03-21 | $2.62M derived: sum of 4 quarters · filed 2022-03-21 | |
| 2020-03-31 | $527.00K 10-Q · filed 2021-05-06 | $500.00K 10-Q · filed 2020-05-20 | $969.00K derived: sum of 2 quarters · filed 2022-03-21 | $1.24M derived: sum of 3 quarters · filed 2022-03-21 | $1.43M derived: sum of 4 quarters · filed 2022-03-21 |
| 2019-12-31 | $442.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $713.00K derived: sum of 2 quarters · filed 2022-03-21 | $903.00K derived: sum of 3 quarters · filed 2022-03-21 | $1.09M 10-K · filed 2022-03-21 | |
| 2019-09-30 | $271.00K 10-Q · filed 2020-11-05 | $461.00K derived: sum of 2 quarters · filed 2020-11-05 | $652.00K 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $190.00K 10-Q · filed 2020-08-05 | $381.00K 10-Q · filed 2020-08-05 | |||
| 2019-03-31 | $200.00K 10-Q · filed 2020-05-20 | ||||
| 2018-12-31 | $469.00K 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |